CXCL12 and neoplasm: To further verify the importance of the fibrocyte-like cells recruited by the CXCL12-CXCR4 axis in the development of bevacizumab resistance in vivo, tumour (Y-MESO-14)-bearing mice were treated with bevacizumab and/or AMD3100.